Amarin Corporation plc (AMRN) key performance indicators and operating metrics (14 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| United States market share | 48.00 percent | FY2026-Q2 |
| European markets where VAZKEPA is available | 11.00 | FY2026-Q2 |
| United States product revenue | 35.6M | FY2026-Q1 |
| European net product revenue | 4.9M | FY2026-Q1 |
| Net product revenue | 43.3M | FY2026-Q1 |
| Non-GAAP adjusted net loss | -1.79M | FY2026-Q1 |
| European revenue | 5.4M | FY2025-Q1 |
| VASCEPA-branded prescription growth | 14.00 percent | FY2026-Q2 |
| Licensing and royalty revenue | 3.13M | FY2026-Q2 |
| Rest-of-world net product revenue | 2.8M | FY2026-Q1 |
| Gross margin on net product revenue | 37.00 percent | FY2026-Q1 |
| Operating expenses excluding restructuring | 23.9M | FY2025-Q3 |
| Non-GAAP adjusted basic and diluted loss per share | -0.02 USD_per_share | FY2025-Q1 |
| Rest-of-world revenue | 11.9M | FY2024-Q4 |
Back to AMRN overview · AMRN earnings · AMRN holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.